(Q46765999)

25 December 2017

title

Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide (English)

1 reference

25 December 2017

1 reference

Mary Buckwalter

1

1 reference

25 December 2017

James A Dowell

series ordinal

2

1 reference

25 December 2017

publication date

1 November 2005

1 reference

25 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

25 December 2017

volume

45

1 reference

25 December 2017

issue

11

1 reference

25 December 2017

page(s)

1279-1287

1 reference

25 December 2017

LIPID-PHOSPHOACETYLMURAMYL-PENTAPEPTIDE AND LIPID-PHOSPHODISACCHARIDE-PENTAPEPTIDE: PRESUMED MEMBRANE TRANSPORT INTERMEDIATES IN CELL WALL SYNTHESIS

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280378

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280378

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280378

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280378

Pharmacokinetics and excretion of dalbavancin in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280378

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280378

21 January 2018

Identifiers

DOI

10.1177/0091270005280378

1 reference

25 December 2017

1 reference

25 December 2017